: Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion


Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based drugmaker said it will offer $9.10 for each share of CTI, which focuses on blood-related cancers and rare diseases. The offer represents a premium of 88.8% over CTI’s the Tuesday closing price of $4.82 per share. “CTI represents a perfect fit for Sobi’s haematology franchise today, adding a powerful and highly differentiated new product that will make a significant difference for patients”, said Guido Oelkers, president and…

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMarket Extra: Why Wednesday’s U.S. inflation report could ignite stock-market volatility as investors boost bets on Fed’s rate cuts
Next articleSwedish Orphan Biovitrum to acquire CTI BioPharma in a $1.7 billion deal


Please enter your comment!
Please enter your name here